Skip to main content

Table 2 Estimated means from models at T2 and T3

From: Duloxetine in OsteoArthritis (DOA) study: effects of duloxetine on pain and function in end-stage hip and knee OA – a pragmatic enriched randomized controlled trial

 

Scale range

Duloxetine intervention

Care-as-usual

Adjusted mean difference

P-value

T2 (after treatment phase)

KOOS/HOOS

  Pain

0–100

45.3 (41.4, 49.2)

34.0 (30.1, 37.9)

11.3 (5.8, 16.8)

< 0.001

  Symptoms

0–100

49.1 (44.7, 53.5)

39.9 (35.5, 44.3)

9.2 (3.0, 15.4)

0.004

  ADL

0–100

47.8 (43.5, 52.1)

37.3 (33.0, 41.6)

10.5 (4.5, 16.6)

0.001

  QOL

0–100

26.8 (22.8, 30.8)

22.3 (18.3, 26.4)

4.5 (0.5, 12.3)

0.124

mPDQ

−1-38

11.7 (10.3, 13.2)

15.4 (13.9, 16.8)

3.6 (1.6, 5.7)

0.001

VAS-past week

  VAS-Rest

0–100

40.8 (34.8, 46.8)

57.8 (51.8, 63.8)

17.0 (8.5, 25.5)

< 0.001

  VAS-Movement

0–100

53.9 (48.9, 59.1)

70.6 (65.6, 75.7)

16.7 (9.5, 23.9)

< 0.001

PGI-Ia

1–7

3.3 ± 1.7

5.0 ± 0.9

1.77 (1.2, 2.3)

< 0.001

  Much or very much better#

 

43.8% (21/48)

0% (0/51)

< 0.001

  Much or very much worse#

 

12.5% (6/48)

33.3% (17/51)

0.018

T3 (after tapering phase)

KOOS/HOOS

  Pain

0–100

43.1 (39.2, 47.0)

36.4 (32.6, 40.3)

6.7 (1.2, 12.1)

0.017

  Symptoms

0–100

44.8 (40.5, 49.2)

41.7 (37.4, 46.1)

3.1 (−2.8, 10.5)

0.325

  ADL

0–100

45.5 (41.2, 49.7)

40.2 (36.0, 44.5)

5.2 (−0.8, 11.2)

0.089

  QOL

0–100

27.0 (23.0, 31.0)

22.3 (18.3, 26.4)

4.7 (−1.0, 10.4)

0.105

mPDQ

−1-38

13.0 (11.6, 14.4)

15.1 (13.7, 16.6)

2.1 (0.1, 4.2)

0.04

VAS-past week

  VAS-Rest

0–100

42.6 (36.6, 48.6)

60.3 (54.3, 66.3)

17.7 (9.3, 26.2)

< 0.001

  VAS-Movement

0–100

58.8 (53.8, 63.8)

69.2 (64.2, 74.3)

10.4 (3.3, 17.6)

0.004

PGI-Ia

1–7

4.0 ± 1.6

5.2 ± 1.1

1.2 (0.7, 1.7)

< 0.001

  Much or very much better#

.

22.5% (11/49)

0% (0/51)

< 0.001

  Much or very much worse#

 

22.5% (11/49)

51.0% (26/51)

0.004

  1. aobserved values; # % (n/N)